Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.64
(-1.28%)
CNY 44.64
(-1.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.06 Billion CNY | 19.67% |
| 2022 | -5.05 Billion CNY | 31.25% |
| 2021 | -7.35 Billion CNY | 24.48% |
| 2020 | -9.73 Billion CNY | -882.82% |
| 2019 | -990.91 Million CNY | -1643.58% |
| 2018 | -56.83 Million CNY | 72.12% |
| 2017 | -203.83 Million CNY | -23.28% |
| 2016 | -165.34 Million CNY | -446.34% |
| 2015 | 47.74 Million CNY | 130.61% |
| 2014 | -155.97 Million CNY | 65.73% |
| 2013 | -455.18 Million CNY | 18.83% |
| 2012 | -560.81 Million CNY | -554.2% |
| 2011 | -85.72 Million CNY | -101.94% |
| 2010 | -42.45 Million CNY | -143.62% |
| 2009 | -17.42 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.79 Billion CNY | 6.69% |
| 2024 Q2 | 900.86 Million CNY | 123.76% |
| 2024 Q3 | 1.44 Billion CNY | 109.15% |
| 2023 Q2 | -4.82 Billion CNY | -5.47% |
| 2023 Q4 | -4.06 Billion CNY | -8.84% |
| 2023 FY | -4.06 Billion CNY | 19.67% |
| 2023 Q3 | -3.73 Billion CNY | 22.64% |
| 2023 Q1 | -4.57 Billion CNY | 9.54% |
| 2022 Q3 | -4.88 Billion CNY | 9.07% |
| 2022 Q2 | -5.36 Billion CNY | 13.56% |
| 2022 Q4 | -5.05 Billion CNY | -3.57% |
| 2022 Q1 | -6.21 Billion CNY | 15.54% |
| 2022 FY | -5.05 Billion CNY | 31.25% |
| 2021 Q3 | -7.45 Billion CNY | 16.87% |
| 2021 FY | -7.35 Billion CNY | 24.48% |
| 2021 Q2 | -8.96 Billion CNY | 2.08% |
| 2021 Q4 | -7.35 Billion CNY | 1.36% |
| 2021 Q1 | -9.15 Billion CNY | 5.95% |
| 2020 Q1 | -662.62 Million CNY | 33.13% |
| 2020 Q3 | -10.67 Billion CNY | -1761.47% |
| 2020 FY | -9.73 Billion CNY | -882.82% |
| 2020 Q4 | -9.73 Billion CNY | 8.74% |
| 2020 Q2 | -573.27 Million CNY | 13.48% |
| 2019 Q2 | -1.34 Billion CNY | -6564.39% |
| 2019 Q4 | -990.91 Million CNY | 29.42% |
| 2019 FY | -990.91 Million CNY | -1643.58% |
| 2019 Q1 | 20.83 Million CNY | 136.66% |
| 2019 Q3 | -1.4 Billion CNY | -4.24% |
| 2018 Q4 | -56.83 Million CNY | 58.0% |
| 2018 FY | -56.83 Million CNY | 72.12% |
| 2018 Q3 | -135.3 Million CNY | 21.64% |
| 2018 Q2 | -172.66 Million CNY | 11.51% |
| 2018 Q1 | -195.11 Million CNY | 4.27% |
| 2017 FY | -203.83 Million CNY | -23.28% |
| 2017 Q1 | -292.47 Million CNY | -76.89% |
| 2017 Q2 | -363.96 Million CNY | -24.44% |
| 2017 Q4 | -203.83 Million CNY | -16.73% |
| 2017 Q3 | -174.61 Million CNY | 52.02% |
| 2016 Q4 | -165.34 Million CNY | -5.29% |
| 2016 Q3 | -157.04 Million CNY | -21.78% |
| 2016 Q2 | -128.95 Million CNY | -157.11% |
| 2016 FY | -165.34 Million CNY | -446.34% |
| 2016 Q1 | -50.15 Million CNY | -205.06% |
| 2015 Q2 | -129.78 Million CNY | 6.17% |
| 2015 Q3 | 23.07 Million CNY | 117.78% |
| 2015 Q4 | 47.74 Million CNY | 106.88% |
| 2015 Q1 | -138.32 Million CNY | 11.32% |
| 2015 FY | 47.74 Million CNY | 130.61% |
| 2014 Q1 | -381.16 Million CNY | 16.26% |
| 2014 Q4 | -155.97 Million CNY | -264.58% |
| 2014 Q3 | 94.76 Million CNY | 125.94% |
| 2014 Q2 | -365.3 Million CNY | 4.16% |
| 2014 FY | -155.97 Million CNY | 65.73% |
| 2013 Q1 | -537.94 Million CNY | 4.08% |
| 2013 FY | -455.18 Million CNY | 18.83% |
| 2013 Q4 | -455.18 Million CNY | 12.92% |
| 2013 Q3 | -522.71 Million CNY | -9.5% |
| 2013 Q2 | -477.38 Million CNY | 11.26% |
| 2012 Q4 | -560.81 Million CNY | -0.61% |
| 2012 FY | -560.81 Million CNY | -554.2% |
| 2012 Q2 | -83.11 Million CNY | 0.0% |
| 2012 Q3 | -557.4 Million CNY | -570.65% |
| 2011 Q4 | -85.72 Million CNY | 0.0% |
| 2011 FY | -85.72 Million CNY | -101.94% |
| 2010 FY | -42.45 Million CNY | -143.62% |
| 2009 FY | -17.42 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 408.143% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -2986.41% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 1086.992% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | -377.527% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | -2278.546% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | -1587.331% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | -473.555% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | -11.727% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -4280.794% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | -734.887% |